Role of genomics in liver transplantation for cholangiocarcinoma

被引:0
作者
Soliman, Nadine [1 ,2 ,3 ]
Maqsood, Anaum [4 ,5 ]
Connor, Ashton A. [1 ,2 ,3 ,5 ,6 ]
机构
[1] Houston Methodist Hosp, Dept Surg, Houston, TX USA
[2] Houston Methodist Hosp, JC Walter Jr Transplant Ctr, Houston, TX USA
[3] Houston Methodist Acad Inst, Houston, TX USA
[4] Houston Methodist Hosp, Dept Med, Houston, TX USA
[5] Houston Methodist Hosp, Neill Canc Ctr, Houston, TX USA
[6] Cornell Univ, Weill Cornell Med, Dept Surg, New York, NY USA
关键词
cholangiocarcinoma; liver transplantation; molecular profiling; next generation sequencing; personalized medicine; ISOCITRATE DEHYDROGENASE 1; BILIARY-TRACT CANCERS; OPEN-LABEL; HILAR CHOLANGIOCARCINOMA; METASTATIC CANCER; NEOADJUVANT CHEMORADIATION; HEPATOCELLULAR-CARCINOMA; LABORATORY STANDARDS; THERAPEUTIC TARGETS; HEPATIC RESECTION;
D O I
10.1097/MOT.0000000000001209
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Purpose of reviewThe purpose of this review is to summarize the current knowledge of cholangiocarcinoma molecular biology and to suggest a framework for implementation of next-generation sequencing in all stages of liver transplantation. This is timely as recent guidelines recommend increased use of these technologies with promising results.Recent findingsThe main themes covered here address germline and somatic genetic alterations recently discovered in cholangiocarcinoma, particularly those associated with prognosis and treatment responses, and nascent efforts to translate these into contemporary practice in the peri-liver transplantation period.SummaryEarly efforts to translate molecular profiling to cholangiocarcinoma care demonstrate a growing number of potentially actionable alterations. Still lacking is a consensus on what biomarkers and technologies to adopt, at what scale and cost, and how to integrate them most effectively into care with the ambition of increasing the number of patients eligible for liver transplantation and improving their long-term outcomes.
引用
收藏
页码:158 / 170
页数:13
相关论文
共 150 条
[1]   Transplant Oncology: An Evolving Field in Cancer Care [J].
Abdelrahim, Maen ;
Esmail, Abdullah ;
Abudayyeh, Ala ;
Murakami, Naoka ;
Saharia, Ashish ;
McMillan, Robert ;
Victor, David ;
Kodali, Sudha ;
Shetty, Akshay ;
Nolte Fong, Joy V. ;
Moore, Linda W. ;
Heyne, Kirk ;
Gaber, A. Osama ;
Ghobrial, Rafik Mark .
CANCERS, 2021, 13 (19)
[2]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[3]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[4]   Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].
Andersen, Jesper B. ;
Spee, Bart ;
Blechacz, Boris R. ;
Avital, Itzhak ;
Komuta, Mina ;
Barbour, Andrew ;
Conner, Elizabeth A. ;
Gillen, Matthew C. ;
Roskams, Tania ;
Roberts, Lewis R. ;
Factor, Valentina M. ;
Thorgeirsson, Snorri S. .
GASTROENTEROLOGY, 2012, 142 (04) :1021-U552
[5]   Screening for circulating RAS/RAF mutations by multiplex digital PCR [J].
Andersen, Rikke Fredslund ;
Jakobsen, Anders .
CLINICA CHIMICA ACTA, 2016, 458 :138-143
[6]   Molecular Profile of Intrahepatic Cholangiocarcinoma [J].
Andraus, Wellington ;
Tustumi, Francisco ;
de Meira Junior, Jose Donizeti ;
Pinheiro, Rafael Soares Nunes ;
Waisberg, Daniel Reis ;
Lopes, Liliana Ducatti ;
Arantes, Rubens Macedo ;
Santos, Vinicius Rocha ;
de Martino, Rodrigo Bronze ;
D'Albuquerque, Luiz Augusto Carneiro .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
[7]   Four DNA Methylation Biomarkers in Biliary Brush Samples Accurately Identify the Presence of Cholangiocarcinoma [J].
Andresen, Kim ;
Boberg, Kirsten Muri ;
Vedeld, Hege Marie ;
Honne, Hilde ;
Jebsen, Peter ;
Hektoen, Merete ;
Wadsworth, Christopher A. ;
Clausen, Ole Petter ;
Lundin, Knut E. A. ;
Paulsen, Vemund ;
Foss, Aksel ;
Mathisen, Oystein ;
Aabakken, Lars ;
Schrumpf, Erik ;
Lothe, Ragnhild A. ;
Lind, Guro E. .
HEPATOLOGY, 2015, 61 (05) :1651-1659
[8]   IMPACT OF COMPREHENSIVE GENOMIC PROFILING OF PATIENTS WITH FIRST LINE NON-SMALL CELL LUNG CANCER IN THE UK [J].
Anhorn, R. ;
Roberts, G. ;
Skovhus, M. ;
Khorshid, M. .
VALUE IN HEALTH, 2017, 20 (09) :A575-A575
[9]  
[Anonymous], 2018, Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer: A Landscape Report
[10]   Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma [J].
Arai, Yasuhito ;
Totoki, Yasushi ;
Hosoda, Fumie ;
Shirota, Tomoki ;
Hama, Natsuko ;
Nakamura, Hiromi ;
Ojima, Hidenori ;
Furuta, Koh ;
Shimada, Kazuaki ;
Okusaka, Takuji ;
Kosuge, Tomoo ;
Shibata, Tatsuhiro .
HEPATOLOGY, 2014, 59 (04) :1427-1434